chrisvoncsefalvay/vaers-outcomes huggingface dataset:
After receiving booster on 11/18, fatigued for 2 days (similar to shot 2), and swollen lymph nodes (for about a week).  Some shortness of breath initially attributed to walking in cold weather and physical condition and pushed through because of thanksgiving visitors.  Day 10 (Nov 30), unable to sleep lying down due to pain.  Kept thinking I had pulled a muscle, but after friends visited December 10-12, they commented on my 'gasping for breath', so I got a covid test on 12/13 that was negative and scheduled an appt on 12/16 with my physician.    On December 16, upon presentation at Dr.'s office, my blood pressure was high and when asked to lie on the exam table, I told her I could not because it was too painful and I had been sleeping sitting up for two weeks.  My doctor recognized quickly I would need some blood work, chest x-rays, and other workups and, given her office is one block from Hospital, her assistant walked there with me and Dr. called the ER attending to speed my admission.  On admission to the ER, my blood pressure was 170/111, pulse 120.  Blood work was done, chest x-ray, chest CT.  Initially thought that perhaps it was pneumonia or a blood clot, but my white blood cell count was normal and I had no fever.  Was administered some IV antibiotics to treat minor infection, and an echocardiogram was scheduled.  Echo showed a moderate pericardial effusion, I was kept overnight in hospital.  On discharge on December 17, I was prescribed 1800 mg of ibuprofen for two weeks, colchicine for three months (2 tabs daily), and a follow-up was scheduled for me with Dr..    On December 27, I met with Dr., where bloodwork was done to check my inflammation levels and whether I had lupus or another autoimmune disease.  While blood work showed declines in inflammation from 12/16/21 hospital levels (unknown to me), they were still quite outside of the normal range at c-reactive of 11 mg/L (normal range <=4) and Westergren ESR of 50 mm/hr (normal range 0-20).
pt recv vax 26OCT98 & that evening began itching all over;noted rash red pinpoint areas all over body especially chest the next AM;referred to physician to discuss cont HepB series;
Swollen lymph nodes. Left underarm and left lower leg (between the knee and foot on the back side of the leg); This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 16Apr2021 at 17:45 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included pre-diabetic, fatty liver, overweight and occasional palpitations. The patient was not allergic to medications, food, or other products. Concomitant medications included metformin (MANUFACTURER UNKNOWN), lecithin (MANUFACTURER UNKNOWN), ascorbic acid (VITAMIN C), colecalciferol (VITAMIN D3) and zinc (MANUFACTURER UNKNOWN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 26Mar2021 at 17:45 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021 at 13:00, the patient experienced swollen lymph nodes in left underarm and left lower leg between the knee and foot on the back side of the leg. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events. The clinical outcome of the events swollen lymph nodes in left underarm and left lower leg between the knee and foot on the back side of the leg was unknown.   No follow-up attempts are needed. No further information is expected.
24 hours after vaccine - knot at injection site, erythema, pain, itching, low grade fever. Erythema 10cm warm to the touch and tender with 2cm firm nodule in center.
Intense arm discomfort/pain and injection site soreness, began around 2 to 3 hours after innoculation, lasted around 36 hours. Severe uncomfortable incessant shivering began at 21:00 12/30 and persisted for an hour. Intense cold sweats began at 20:30 12/30 and lasted around 18 hours, this symptom was also accompanied by a fever with a peak of 101.7° that lasted a similar duration. Unpleasant yet bearable body aches manifested the morning of 12/31 around 08:00 and did not subside until the next day. Throbbing, sharp headache began 12/30 at 13:00  and persisted until 12/31 around 19:00. 325mg of enteric coated aspirin was taken on three different occasions, 12/30 at 21:30, 12/31 at 08:30, and 1/1  at 00:30. 1,000mg of acetaminophen was also ingested on 1/1 at 00:30. All symptoms dispersed by noon of 1/1 and have not reoccurred.
Developed rash of small, raised, pink bumps covering arms, legs, across the shoulders on his back, and on his left cheek.
Patient experienced dizziness, nausea, Feeling faint, Problems with her vision, ringing in the ear and  she felt she had to defecate. She described it as passing out 3 times. Tingling in hands, being cold. She was not feeling better after 20 minutes so 911 was called and she was taken to the ER by paramedics. I spoke to her mom the following day she was released and feeling better.
Fever , My bones hurt legs and arms low part of my back  My head hurt so bad sick to my stomach
Morning after the COVID19 shot, experienced fatigue, chills, fever, and headache (general flu-like symptoms).  Minimal injection site pain.  Symptoms persisted for roughly 12 hours and then stopped.  No recurrence or additional symptoms followed, no treatment needed.
Eczema breakout on face. Progressively worse, got infected and unresolved at present. Started after first dose but got a lot worse after second dose. Dermatologist prescribed antibiotics, antidungal, and anti inflammatory cream. Treatments have calmed it down but not cured it so far.
mild low-grade fever; headache; hard to stand energy wise; pain in uterus/ovary areas within 8 hours of vaccine; shakiness until two days after; This is a spontaneous report from a non-contactable consumer, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the left arm on 24May2021 at 15:15 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient was allergic to gluten which had some small impact but she could eat it. Concomitant medications included ascorbic acid, herbal nos, levoglutamide, lysine, magnesium, manganese, retinol, riboflavin, selenium, tocopherol, zinc (AIRBORNE), vitamin D (MANUFACTURER UNKNOWN) and women's multivitamins (MANUFACTURER UNKNOWN), all taken for unspecified indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the left arm on 03May2021 at 15:00 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24May2021 at 23:15, within 8 hours of vaccine, the patient experienced pain in uterus/ovary areas, it was not related to her period cycle as that had been over two weeks prior and the pain lasted the following day, it was intensified when breathing deeply or sucking in stomach. On 24May2021, the patient experienced shakiness until two days after. On 25May2021, the day after the vaccine not until 5 hours into work, the patient experienced mild low-grade fever, headache and hard to stand energy wise, the headache was intensified when vertical through the rest of that day. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events pain in uterus/ovary areas and shakiness were resolved on 25May2021 and 26May2021 respectively, while the outcomes of mild low-grade fever, headache and hard to stand energy wise were resolved on an unknown date on May2021.   No follow-up attempts are possible. No further information is expected.
Patient contracted COVID after being fully vaccinated Headache, Sore Throat, Cough, Nausea, Chills, Muscle Aches, Fatigue, Congestion
After vaccination, patient reports swelling to the size of a golf ball over the course of 3 days.  Patient went to urgent care.  They determined that the vaccine had inadvertently been administered sub-q, not IM, leading to granuloma formation.  Urgent care outlined site of reaction and instructed patient to take antiinflammatories until swelling subsides; if swelling increases beyond the drawn border then go to ER.  Swelling decreased over the next several days, only small amount of redness remains on 2/8.
ONE DAY POST GARDASIL ADMINISTRATION, PT HAD SUB-DELTOID BURSITIS WITH PAIN AND WEAKNESS.  SHE WAS UNABLE TO LIFT ARM FOR 1-2 WEEKS.  PT REFERRED TO SPORTS MEDICINE FOR INPUT.
Immediate slight dizziness, continued for 1.5 hours, slight headache. Then 1.5 hours post vaccination syncope, fall to floor. ER workup was clear immediately following event, no abnormal testing, labs and ekg all normal.  1 week post vaccine, no other symptoms aside from sore arm.
Pt was inadvertently given a booster dose of 0.25 mL of Moderna vaccine. Pt is not of age to receive this vaccine. No adverse reaction reported by pt or family at this time.
passed out about 7 to 8 times; Pain on the right side of body; Dizziness; Felt like golf ball in right chest; Couldn't breathe; Nausea; Fever; Injection site redness; Outer part of the skin is bumpy; A spontaneous report  was received from a consumer, a 46-year-old female patient, who was administered Moderna's COVID-19 vaccine (mRNA-1273) and experienced passed out about 7 to 8 times/loss of consciousness, pain on the right side of body/pain, dizziness, felt like golf ball in right chest/chest discomfort, couldn't breathe/dyspnea, nausea, fever/pyrexia, injection site redness/injection site erythema and outer part of the skin is bumpy/injection site reaction.  The patient's medical history included was migraine. Product known to have been used by the patient, within two weeks prior to the event, included was ibuprofen for migraine.  On 12 Jan 2021, the patient received their first of two planned doses of mRNA-1273 (Lot number: 011J20A) intramuscularly in her left arm for prophylaxis of COVID-19 infection.  On 12 Jan 2021, the patient experienced feeling a lot of pain on the right side of her body and the shot was given on her left arm. Fever, nauseous, supper dizzy, passed out about 7 to 8 times, felt like she got a golf ball in her right chest, red on the injection site, the outer part of the skin is all bumpy, couldn't breathe. Treatment for the events included were ibuprofen and diclofenac injection.  The Action taken with the second dose of mRNA-1273 in response to the event was not reported.   The outcome of the events, passed out about 7 to 8 times/loss of consciousness, pain on the right side of body/pain, dizziness, felt like golf ball in right chest/chest discomfort, couldn't breathe/dyspnea, nausea, fever/pyrexia, injection site redness/injection site erythema and outer part of the skin is bumpy/injection site reaction were considered as unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Further information has been requested.
The patient reported instant pain at the time of injection which caused him to jump.  He said that night he was unable to sleep well due to pain radiating down his arm. His wife is an RN, and she advised him to take some ibuprofen and apply an ice pack, which he did. The pain continued to worsen, and he began noticing tingling in the fingers of the left hand, and a loss of strength in the arm. He then sought care from his primary care physician on approximately 7/14/17. He was prescribed prednisone 20mg tabs, 60mg x 3 days, 40mg x 3 days, 20mg x 3 days. He visited me today, 7/18 to give me this report. He was still experiencing pain.
pt recv vax & 15-20min later devel diffuse urticarial rash all over body;given/epi & DPH w/good results;pt d/c to mom;
Sore right arm; Sleepiness; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of LIMB DISCOMFORT (Sore right arm), SOMNOLENCE (Sleepiness) and FATIGUE (Fatigue) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016C21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in January 2021.    On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Apr-2021, the patient experienced LIMB DISCOMFORT (Sore right arm), SOMNOLENCE (Sleepiness) and FATIGUE (Fatigue). At the time of the report, LIMB DISCOMFORT (Sore right arm), SOMNOLENCE (Sleepiness) and FATIGUE (Fatigue) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was provided.   No treatment medication was provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-May-2021: Follow-up information included no new information. On 03-Aug-2021: Event outcome updated.
This spontaneous report as received from a medical assistant refers to unspecified number of patients of unknown age and gender. On an unknown dates in 2014, unspecified number of patients were vaccinated with GARDASIL (lot number, Expiry Date, dose, route were note reported), that was improperly stored in April 2014. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
This patient was admitted on 8/10/2021 with COVID-19 infection and pneumonia versus COPD exacerbation.  Patient was treated with oxygen, Actemra, ivermectin, dexamethasone, vitamin C, vitamin D, and melatonin.  He had thrombocytopenia and Pepcid was stopped.  Developed leukopenia but this improved by date of discharge.  His highest oxygen level was 7 L.  Actemra seems to be the medication that helped his clinical condition improved and he was discharged on 8/12/2021.
Injection site pain; injection site erythema Information has been received from a registered nurse concerning a 67 year old female patient with a history of immunization in 2000 and unknown drug reactions/allergies reported who one 28-OCT-2005 was vaccinated intramuscularly in the left deltoid with a 0.5ml booster dose pneumococcal 23v polysaccharide vaccine (lot  #649914/0578P). Concomitant therapy included metoprolol succinate (Toprol XL tablets) raloxifen hydrochloride (Evista) and vitamins unspecified. It was reported that the patient received her first dose of pneumococcal 23v polysaccharide vaccine (route, dose and L# unknown) in 2000. Within 12 hours of vaccination, on 28-OCT-2005 the patient experienced her left arm became sore and red at the injection site. She did not have a fever. The pain was relieved with ice packs and acetaminophen (Tylenol). Subsequently, on an unknown date, the patient recovered. No product quality complaint was involved. Additional information has been requested.
This is a spontaneous report from a contactable physician via Pfizer sales representative. A patient of unspecified age, race and gender received TRUMENBA, via an unspecified route of administration on an unspecified date at single dose for immunisation. The patient medical history and concomitant medications were not reported. The patient experienced first dose of TRUMENBA reoccurring after the second or third dose of TRUMENBA, specifically regarding pain in the general area of the injection on an unspecified date with outcome of unknown.
itchy at injection site; Rash; Tired all day/fatigue,; blowing her nose; nose was stuffed up; sneezing; This spontaneous case was reported by a consumer and describes the occurrence of RHINORRHOEA (blowing her nose), NASAL CONGESTION (nose was stuffed up), SNEEZING (sneezing), VACCINATION SITE PRURITUS (itchy at injection site) and RASH (Rash) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 019B21A and 032M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy NOS.   On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 08-Apr-2021, the patient experienced RHINORRHOEA (blowing her nose), NASAL CONGESTION (nose was stuffed up), SNEEZING (sneezing) and FATIGUE (Tired all day/fatigue,). On 09-Apr-2021, the patient experienced VACCINATION SITE PRURITUS (itchy at injection site) and RASH (Rash). The patient was treated with PARACETAMOL (TYLENOL) 08-Apr-2021 for Adverse event, at a dose of 1 dosage form(1 tablet at night before bed). On 10-Apr-2021, FATIGUE (Tired all day/fatigue,) had resolved. At the time of the report, RHINORRHOEA (blowing her nose), NASAL CONGESTION (nose was stuffed up), SNEEZING (sneezing), VACCINATION SITE PRURITUS (itchy at injection site) and RASH (Rash) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Apr-2021, Body temperature: 99 (Inconclusive) 99.         No concomitant medications were reported.
Distension, abdominal tenderness Medial visual field loss in left eye. Covid pneumonia, TIA suspected from Covid
Tiredness first day after dose, second day 1/5/21 after 4PM extreme nausea, diarrhea, sore throat, and some SOB or labored breathing. Felt better after 1/6/21 after 4PM.
Patient reports a little swelling and pain the following day on 2/15, which has persisted and has stayed "tender to the touch/sore around the site" for the past week. The swelling grew to the point of about a baseball, and has since progressively decreased to about the size of a golf ball. Today on 2/21/23 it has decreased to about the size of a pea, but it is still red, tender, and warm to the touch.
Drug effect incomplete; COVID VACCINE not as effective; This is a solicited report based on the information received by Pfizer from pharmaceutical company (MFR control no.: 21K-163-4051654-00) from a contactable consumer (patient) reported for himself.  A 16-year-old male patient received bnt162b2 (BNT162B2), dose 1 intramuscular on 09Aug2021 (Batch/Lot number was not reported, at age of 16 years old) as single dose for COVID-19 vaccination; adalimumab (HUMIRA), subcutaneous from an unspecified date (Batch/Lot number was not reported) to an unspecified date, at facility for moderate to severe pediatric crohns disease moderate to severe polyarticular. The patient medical history was not reported. The patient's concomitant medications were not reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. In Aug2021, the patient experienced COVID VACCINE not as effective while on HUMIRA. The action taken in response to the events for adalimumab was not applicable. The outcome of events was not recovered. Causality for HUMIRA(ADALIMUMAB): The reporter's causality for the event(s) of COVID VACCINE not as effective while on HUMIRA was not provided. Causality for bnt162b2: The reporter's causality for the event COVID VACCINE not as effective while on HUMIRA was unrelated per reporter.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the information available and a possible contributory role of the suspect BNT162B2 to the reported events of  LOE can be completely excluded/unrelated;The case will be reassessed once new information is available.
Mixed series: Patient received the first dose as Moderna Covid19 Vaccine, and the second dose as Pfizer Covid19 Vaccine.; This spontaneous case was reported by a pharmacist and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Mixed series: Patient received the first dose as Moderna Covid19 Vaccine, and the second dose as Pfizer Covid19 Vaccine.) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Mixed series: Patient received the first dose as Moderna Covid19 Vaccine, and the second dose as Pfizer Covid19 Vaccine.). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (Mixed series: Patient received the first dose as Moderna Covid19 Vaccine, and the second dose as Pfizer Covid19 Vaccine.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication information was provided. No treatment medication information was provided.
This spontaneous report as received from a physician via company representative refers to a female adolescent patient. There were no concomitant medications, concurrent conditions and medical history reported. On an unknown date in 2015 (reported as around 6 months ago), the patient was vaccinated with GARDASIL (dose, route and site of administration, lot and expiration date were unknown). It was unspecified if this was the first, second or third shot in the GARDASIL series. On an unknown date in 2015 (reported as "shortly after" receiving the GARDASIL), the patient began to experience neurological problems, including "difficulty walking and getting around". The patient sought unspecified medical attention. These symptoms had led to a significant change in the adolescent's lifestyle, including the need to quit cheerleading. The outcome of the events was unknown. The relatedness between the events and GARDASIL was not reported. Upon internal review the events of difficulty in walking and mobility decreased were considered to be disabling. Additional information has been requested.
Rash inj site sore day 1, rash at inj site on day 5, 6, 7 Narrative:
Radiating pain in the neck. Can't move her arm - shoulder joint. Hematoma.
Left arm erythema, swelling, papules, induration. Treated for cellulitis/allergic reaction.
I had a schedule 07/13/2021 women's wellness check. At that appoint they performed labs of blood work. I received the results of the test on 07/14/2021 and referred to the Hospital for sodium infusion. 07/16/ 2021, went back to Doctor: due to fluction of sodium levels . New issue with sodium and new issue with sodium dropping. 08/1/2021 was admitted larger Hospital, abnormal labs, 124 sodium when I was admitted. Really sick with illness, Sodium level is dropping low and not the tablets can not keep sodium up and having to migraines 126 sodium and fluids with sodium 3 times a day. 03/24-25/2021 uncontrolled seizures 129 sodium. Hospital from seizures and high blood pressure, 03/29/2022. Given Steroid and Reglen to help the headache dissipate.